Comment on 'AIRE-deficient patients harbor unique high-affinity disease-ameliorating autoantibodies'.

Landegren N, Rosen LB, Freyhult E, Eriksson D, Fall T, Smith G, Ferre EMN, Brodin P, Sharon D, Snyder M, Lionakis M, Anderson M, Kämpe O

Elife 8 (-) - [2019-06-27; online 2019-06-27]

The AIRE gene plays a key role in the development of central immune tolerance by promoting thymic presentation of tissue-specific molecules. Patients with AIRE-deficiency develop multiple autoimmune manifestations and display autoantibodies against the affected tissues. In 2016 it was reported that: i) the spectrum of autoantibodies in patients with AIRE-deficiency is much broader than previously appreciated; ii) neutralizing autoantibodies to type I interferons (IFNs) could provide protection against type 1 diabetes in these patients (Meyer et al., 2016). We attempted to replicate these new findings using a similar experimental approach in an independent patient cohort, and found no evidence for either conclusion.

QC bibliography QC xrefs

PubMed 31244471

DOI 10.7554/eLife.43578

Crossref 10.7554/eLife.43578

43578

pmc PMC6597240